Abstract: Microbiome research has experienced an unprecedented level of growth over the last decade. This is largely due to revolutionary developments in, and accessibility to, DNA sequencing technologies that have enabled laboratories with even modest budgets to undertake projects. Study of the human microbiome in particular has seen a surge in interest, and although a lot of time and money has been focused on health and disease, the clinical interpretation of these data and the ability of clinicians to understand these studies in the context of disease are less straightforward. Conditions such as inflammatory bowel disease, asthma, and cancer have seen a huge increase in research focused on the role of microbiome in disease pathogenesis, but the ability of clinicians to appraise and use these data is largely lacking. The purpose of this article is to provide an introduction for clinicians and nonclinicians wishing to learn about and engage in microbiome research. It details the background of microbiome research and discusses the process of generating 16S rRNA sequencing data, the most commonly used method for microbiome analysis. We discuss the interpretation of results in a clinical context, commonly used metrics for analysis and discuss future impact and direction for microbiome research. The meteoric rise of genomic medicine to the brink of routine clinical use should be seen as a blueprint for the microbiome; the ability for physicians to understand and interpret these data is vital to this growth and aiding clinicians (and researchers) to participate in further microbiome research.
T he advent of high-throughput next-generation sequencing has revolutionized genetic research; since the completion of the human genome project in 2003, a whole human genome can now be sequenced for a fraction of the cost and in a fraction of the time. Over the last 5 to 10 years, this technology has begun to be applied to bacteria, with coining of the term microbiome to describe "the collective genomes and gene products of all microbes residing within an organism." 1 Study of the human microbiome in the context of disease has seen a surge in interest. Although a lot of time and money has been focused on several disease areas, the clinical interpretation of these data and the ability of clinicians to interpret these studies in the context of understanding and management of disease has lagged behind. To address this gap, this review is targeted at those wanting to understand and interpret microbiome results and data; we discuss basic science aspects, techniques for investigation, analysis, and interpretation of data.
The virome and mycobiome are, respectively, the viral and fungal equivalent of microbiome, 2, 3 details of which are beyond the scope of this review.
WHAT IS THE MICROBIOME AND WHY IS IT IMPORTANT?
The microbiome is "the collective genomes and gene products of the microbiota residing within an organism." 1 In normal healthy individuals, microbiota exists on all parts of the body that come into contact with "the outside world." Bacteria at certain body sites have long been believed to be involved in immune modulation/programming, in the development of disease, 4, 5 and in maintaining health. 6, 7 Currently, 16S rRNA sequencing for microbiome analysis has been used solely as a research tool. The potential to use rapid sequencing to characterize and understand the impact of bacteria on diseases (not classical infectious disease) is huge, and a parallel to the rapid emergence of human genetics and genomics in a clinical setting cannot be overlooked.
The Human Microbiome Project is an attempt by the National Institute of Health to characterize microbial communities at various sites on the human body. 1 This project has been ongoing since 2007 and has widely published on health and disease. There is an aim to produce reference data alongside detailing the role that the microbiome has in disease. 5. 16S ribosomal RNA: bacterial small ribosomal subunit; the DNA coding for this contains highly conserved areas situated between 9 highly variable regions (V1-9). 10 A number of sequence repositories are available, such as Greengenes, which is a comprehensive collection of regularly updated freesource 16S rRNA gene databases. 11 6. Dysbiosis: an imbalance or shift in microbiota at a given body site to an altered state. 12 7. Taxonomy: classification of organisms into groups based on their characteristics (for bacteria, this is often their genetic similarity). 8. Phylogeny: a description of evolutionary relatedness among a group of organisms. 9. Operational taxonomic unit (OTU): microbial 16S sequences are grouped together at a level of similarity (variable) to indicate a single "taxonomic unit." For example, all sequences with 94% similarity are grouped together into a single genus. 13, 14 10. Next-generation sequencing: a catch-all term used to describe several modalities of high-throughput sequencing technologies. 15 11. Primer sequence: in the context of microbiome sequencing, these are the DNA primer sequences used to amplify a specific variable region(s) within the 16S rDNA gene. 12. FASTQ file: text-based format containing multiple nucleotide sequences each with a per-base quality scores. 13. Barcode sequence: a sample-specific DNA sequence (code or tag) that is incorporated into the DNA to be sequenced at the point of amplification. It allows linking of output sequences back to their samples of origin. 14. LINUX/UNIX: a modular operating system that uses a single "kernel" for all processes. Additional devices/programs can be added as modules. It used a command-line interface (or graphical user interface). LINUX is an example of an open-source software operating system.
WHAT SAMPLES CAN YIELD MICROBIOME DATA?
Almost any biological sample can be used to derive bacterial DNA. 8 The most commonly used samples are biopsies (GI, skin, and lung tissue), washings/scrapings (such as bronchoalveolar lavage), and fluids/bodily products (such as faeces and sputum). The source of sampling does not impact on the technology used for subsequent 16S analysis, but all samples undergo specific processing (dependant on their type) to extract bacterial DNA. Certain samples with low bacterial biomass are likely to have low yields of DNA; it is vital to be able to recognize this and interpret with adequate controls in these scenarios.
Storage of samples before processing is critical; some bacteria will lyse and their DNA will degrade, whereas some will multiply after sampling, leading to misleading or incorrect results. Generally, samples are frozen as soon as possible and some (such as tissue samples) are stored in solutions to preserve DNA/RNA (such as RNAlater [various manufacturers]).
WHICH DISEASES TYPES MAY BE OF INTEREST TO MICROBIOME RESEARCHERS
Microbiome research has not focused on classical infectious illnesses; most clinicians will be aware of targeted sequencing or PCR testing for common infectious bacteria such as Neisseria meningitidis. 16S sequencing is much broader and gives little or no information about subspecies and antibiotic sensitivities that are important to the clinicians. Most publications relate to disease in which host-microbe interaction is likely to play a role in disease pathogenesis and ongoing disease flare; these are mostly chronic conditions such as inflammatory bowel disease (IBD), 4, [16] [17] [18] asthma, [19] [20] [21] skin conditions, 22 and cancers. [23] [24] [25] The immunomodulatory effect of the microbiome seems likely to hold a key to understanding several diseases, and correlation of host gene expression (transcriptome) with the microbiome and microbial gene expression may yield useful insights. 16, 18, 26 Trials have begun to look at the effect of specific modulatory diets on the gut microbiome, largely in the context of IBD 17, 27 and IBS. 28 These have revealed initial dysbiosis with changes in diversity through treatment and have started to understand the functional impact, such as on short-chain fatty acid synthesis. This uses additional software (such as PICRUSt) after initial microbiome analysis. 28, 29 Increasingly, there is interest in the role the microbiome may play in the development of obesity and type 2 diabetes, 30, 31 and alongside this, there has been a small amount of work into acute conditions such as necrotizing enterocolitis in preterm infants looking for evidence of a role of bacteria in such conditions.
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NEXT-GENERATION SEQUENCING (NGS)
NGS is a catch-all term used to describe several modalities of high-throughput sequencing technologies that were developed in mid 2000s. 15 Classical DNA sequencing (Sanger sequencing 36 ) was developed in the 1970s and uses chain termination by dideoxynucleotides and detection of fluorescence of these molecules. It was this technology that led to our first insights into the human genome, 37 although at great cost in both time and expense. The lack of throughput made this technology less than ideal for studies of complex microbial communities, and it was technical advances in sequencing chemistry that led to the widespread adoption of NGS as a tool for microbiome research. Two recent reviews by Land and Loman in 2015 provide excellent insights into the development of bacterial genetic sequencing over the last 20 years.
38,39
Illumina
Illumina sequencing by synthesis is the most widely used sequencing technology for microbiome research. 40 The method works by a reversible dye terminator technology; DNA is ligated into short sections with the addition of identification and primer sequences at either end and attached to a lane (flow cell); it is amplified using polymerase-forming DNA clusters. Fluorescently labeled reversible terminator bases (1 color for each base) are added, which fluoresce when added to the sequence. A camera captures each base as it is added and can relate this to the location of the DNA on the lane. For each sequence, several 100 reads are generated. 40 The Illumina MiSeq is typically used and has a single read length of up to 300 bp and can produce up to 50 million paired-end reads per run.
For microbiome research, primers are used in presequencing PCR to amplify a specific region of the 16S rRNA sequence. These primers include the additional primer and identification sequences mentioned above, and thus, when loaded into the instrument, this PCR product becomes the target for the sequencing reaction generating many 16S rRNA gene-specific reads that then can be related to individual bacteria.
Roche 454
Originally an incredibly popular sequencing technology for microbiome studies, the iterative increases in read length by Illumina (longer reads being the original benefit of using 454) have largely rendered it redundant. 41 
Others-IonTorrent, PacBio, and MinIon
The overwhelming majority of 16S sequencing has been done using Illumina and 454 technologies. Several other companies have their own sequencing technology; some, such as PacBio and MinIon, are real-time single-molecule platforms that may, in time, become highly useful for 16S rRNA sequencing for microbiome analysis. 42 HOW SEQUENCING 16S rRNA ALLOWS BACTERIA TO BE IDENTIFIED?
The ubiquitous and phylogenetically stable bacterial 16S rRNA offers a very useful target for the identification bacteria down to species level in some instances. The 16S ribosomal subunit in encoded for by DNA that has highly conserved regions (very similar sequences) between all bacterial species. Between these areas are highly variable regions (V1-9) that can be used to identify a specific genus or species of bacteria through the sequence. [43] [44] [45] Universal primers are designed to amplify a specific variable region of the 16S rRNA sequence. Based on a combination of best primer sites and information gathered from variable regions, the most commonly targeted regions are V3, V4, and V6. 46 Different primer sets exist for amplification of variable regions, 47 and the choice should be based on the sample type and importance of taxonomy or phylogeny. 48, 49 See Figure 1 for the structure of 16S rDNA.
After sequencing, each read of a 16S rRNA gene is clustered together with others by computer analysis into operational taxonomic units (OTUs) based on how similar the sequences are. It is prudent to remember that grouping together bacteria based on their genetic similarity is somewhat arbitrary. Historically, all species were defined on phenotypic characteristics, and then their genetic similarity was discovered. In microbiome sequencing, bacteria are clustered depending on their genetic similarity and then defined as a genus, species, etc. For example, all sequences with 94% similarity may be grouped together, 8, 9 and referencing a representative sequence for the cluster (OTU) to a reference database allows for identification of the bacteria present at genus level. Grouping at 97% similarity may allow identification at a species level. The relative frequency of the sequences allows for relative abundances of bacteria to be identified within a sample.
HOW ARE SEQUENCING DATA ANALYZED?-COMPUTING PIPELINES
Output data from nearly all sequencing technology is in the form of ".fastq" files; these contain the specific sequence, primer sequences, barcode sequences, and quality information on the sequencing read, i.e., the per-base sequencing reliability score.
Analysis of these data is through computing pipelines using command-line inputs; typically, these are based on UNIX/LINUX operating system commands. Commands (specific actions for a computer to run) are entered into the command-line, which then runs scripts (programs) and the output are files or directories (equivalent to folders).
Several software packages exist for processing sequencing data. Many of these are freely available and have been produced by academic collaboration. In this study, we focus on the 2 most commonly used ones. Quantitative Insights into Microbial Ecology (QIIME) QIIME was developed by collaboration between the University of Colorado and Northern Arizona University. It is freely available as a download and can be installed on a home PC (through a VirtualBox) or Mac.
13 QIIME is actually a collection of many programs allowing for a huge amount of customization of output data; however, as each stage is analyzed separately, there is some added complexity to processing data. QIIME uses command-line inputs. A basic pathway for analysis of data is shown in Figure 2 . Output from initial analysis in the form of a simplified taxonomy summary table is provided in Table 1 . Further analysis of this output data can be performed within QIIME, and this is discussed below.
Mothur 50
Mothur is a widely used software package, developed at the University of Michigan that allows for analysis of 16S rRNA sequencing data using a very similar pipeline to QIIME. It has the advantage of being a single program to run but lacks some of the easy customization of QIIME. Output from QIIME and Mothur has been compared and is most often extremely similar. 51 
INTERPRETING RESULTS-WHAT DOES MY DATA MEAN?
The output data from basic 16S rRNA analysis requires interpretation. Although basic output such as a taxonomic summary shows the bacteria present (to all taxonomic levels) and their relative abundances within a sample, further analysis is needed to understand the quality of the data, the diversity within/between the samples, the species richness of the samples, and ultimately the statistical comparisons needed to determine whether a microbiome has experienced flux or dysbiosis. It must be remembered that many of the underlying tests included in these analyses have been directly drawn from ecological methods of species observations and are not specific for microbes.
Diversity Analysis-How Many Different Taxa are in My Sample?
Alpha diversity is the measure of diversity within a single sample (community). 49 Sample-specific values for alpha diversity can be compared. The most basic form of alpha diversity is simply the number of species seen in a sample; however, this is often unhelpful as there is no measure of frequency of species, estimates of unseen species, etc.
Chao1 is a commonly used measure of alpha diversity 52 ; this is mathematically derived and estimates the number of OTUs that are undetected by sequencing based on the number of bacterial taxa represented by a single read, "singletons." Samples with higher numbers of singletons are estimated by Chao1 as having increased species richness, and therefore higher alpha diversity. Values range from 0 to greater than 10,000.
Shannon diversity is another measure of alpha diversity 53 ; originally proposed as a measure of entropy (disorder) within text. This measure can be interpreted as follows; if all bacteria were placed in a list, the Shannon diversity measures the likelihood that one would guess the next bacteria (species) in the list. Hence, if there were 100 bacteria, 90 of which were firmicutes, the likelihood of predicting the next bacteria as FIGURE 2. Basic data-processing pathway (pipeline) in QIIME.
a firmicutes is very high; and hence the Shannon diversity would be low (close to 0). If there are 100 bacteria, 10 each of 10 different species, then the ability to predict the next bacteria is low and the Shannon diversity would be high. Values are typically 1.5 to 3.5 but may be higher in some microbiome analysis.
Rarefaction is another measure of alpha diversity and assesses species richness through construction of rarefaction curves. These are produced by plotting microbial diversity against depth of sequencing, an example is shown in Figure 3 . These can be used to assess whether the depth of sequencing is sufficient to truly sample all species present within a community. 49 Beta diversity is the measure of diversity between samples. Bray-Curtis dissimilarity is possibly the most commonly used measure 54 ; it describes the dissimilarity between the bacterial compositions of samples and is based on the species numbers at each site. It is expressed on a scale of 0 to 1, where 0 indicates identical samples and 1 represents no species shared between samples.
Unweighted UniFrac 55 is another measure of beta diversity, specific to microbiome research; it incorporates relative relatedness of bacteria with a sample (community) into the calculation and subsequent score. The score is derived by observing the taxa that are seen in both samples (and those that are individual to a sample) and then calculating total branch distances (an evolutionary measure of how closely related bacteria are) between shared and unshared bacteria on a phylogenetic tree. Weighted UniFrac also takes into account the relative abundances of bacteria within the samples.
What Further Statistical Analysis can be Done?
Principle coordinates analysis (PCoA) is increasingly common. 56 This presents each sample (bacterial community) as a data point on a 2-or 3-dimensional graph; similar samples cluster together. The axes of the graph represent the "principle coordinates" of the bacterial community. A simple example is provided in Figure 4 .
Interesting Ways of Representing Data-Heat Maps, Networks
Heat maps have become a popular way of presenting 16S data; there are several ways that heat maps can represent various microbiome data. The most basic heat maps compare OTUs within samples, in which different colors represent different abundances in the samples. An example comparing bacterial genera is shown in Figure 5 .
Correlation networks are a way of visualizing how bacterial species and other factors-fatty acids, host factors, diversity measures-interact. This is often used to compare diseased and healthy groups, demonstrating which bacteria/factors coexist and which do not. 57 
FUNCTIONAL IMPACTS OF THE MICROBIOME
The ability to infer functional impact of a bacterial community is a further stage of microbiome research. Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) 29 is software that references known bacterial genomes to infer the genes present in bacteria that have been identified from 16S sequencing. This process allows for functional predictions about a bacterial community based on the metagenome, which has been inferred from 16S sequence.
An example of this can be found in articles by Gevers et al 
CLINICAL VARIABLES IMPACTING
THE MICROBIOME
Impact of Antibiotics
The number of variables that impact on, and alter, the human microbiome are too numerous to describe in this review. In a clinical context, antibiotics are perhaps the most important and common variable that can have a huge bearing on the microbiome of many sites; it is well described that antibiotic use in IBD amplifies the intestinal dysbiosis 4 and in non-IBD conditions, the gut flora is significantly altered by antibiotics, and this change can last for many months.
21,59-61
Impact of Diet
Another important variable is the impact of diet, specifically on the gut microbiome. It is known that certain gut flora are associated with specific types of diet, and this can make interpretation of results more difficult. 62 
The Newborn
There has been an increase in interest centered around early bacterial colonization of the newborn infant; although vaginal birth is likely to result in a "normal" gut and skin flora in a baby in the first few days of life, the impact of a cesarean section on 
CURRENT APPLICATIONS AND CAUTION IN MICROBIOME INTERPRETATION
Although our ability to characterize microbiomes in both health and disease states has led to the swathe of publications, clinical interpretation of such findings has lagged behind. The ability to robustly interpret microbiome data has emerged over the last 5 to 10 years. The science is reliable, and there are an increasing number of large studies in the literature. However, despite many publications using current technology, there are still reports of potential pitfalls, such as over-or undersequencing of bacteria and misrepresentation of true numbers, in the interpretation of data. 65 Furthermore, the interpretation of results from a clinical perspective remains extremely uncertain with reliability and relevance of data needing to be examined before routine clinical application.
Without consensus on what is normal in health, it is difficult to understand the impact of the microbiome on individuals; inferring causality from correlation of microbiome results and disease is dangerous and further experimental work is needed. 66 It is known that there is huge interindividual microbiome variation at many body sites, especially the gut 67, 68 ; the work of the Human Microbiome Project to vastly increase the number of microbiome profiles of healthy individuals is extremely important in future FIGURE 3. Rarefaction curves. Sample 1 (red line) may represent inadequate sequencing depth; the curve indicates that more OTUs would be found with the additional sequence number as the curve continues to rise beyond the maximum sequence number (not flattening out). Sample 2 (green) represents adequate sequencing depth; the curve flattens indicating that few additional OTUs will be identified even if the sample was sequenced in more depth.
research and clinical interpretation. 8 Further insights into what contributes to this normal variation is an important area of work. 69, 70 
FURTHER APPLICATION
We are at a point of transition-from observation and description to functional analysis and inferring causality. Understanding the host gene expression and functional impacts of microbiome in health and disease may help build evidence to infer the role that bacteria play in disease. 16 The understanding of the immunoregulatory role that microbes are presumed to play is extremely exciting, and we are at the start of a hugely important period in our understanding.
Currently, it seems unlikely that 16S sequencing will be used in the in diagnosis of acute infectious disease, in which accuracy, antibiotic sensitivity, and reliability are paramount, but there have been previous attempts. 71 In the future improved technology may allow the application of microbiome sequencing for routine sequencing, potentially identifying specific genes related to antibiotic resistance and allowing rapid diagnosis and treatment of infections to become routine practice. Understanding broad microbial shifts and dysbiosis in immunodeficient individuals may help to prevent some infections associated with this group of conditions. 72 
CONCLUSION
The human microbiome seems to play a key role in maintaining health and also in the pathogenesis of many chronic diseases. Over the next 5 years, it will become increasingly important for clinicians to understand the impact of the microbiome on normal development, disease, and treatment. The meteoric rise of genomic medicine to the brink of routine clinical use can only be seen as FIGURE 4. Example of a 2-dimensional (2D) principle coordinate analysis. Plot of first 2 principle coordinates (PC) for 20 samples generated using unweighted UniFrac analysis. PC1 (x-axis) accounts for 12.3% of total variation, and PC2 (y-axis) accounts for 10.8% of total variation. Clustering of samples indicates that they are more similar; the sample type can then be used to understand relationships between samples and overall shifts in the microbiome. Here, we show samples classified by 3 different treatment types (A, B, and C) and their subsequent clustering. a blueprint for microbiome researchers; the ability for physicians to understand and interpret 16S data is vital to this growth and to the transition to a generation of microbiome-literate clinicians.
